Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 278

1.

Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG.

Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang RW, Dickinson M, Ng A, Roberts KB, Gao S, Balogh AG, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras JP, Wright C, Kelsey CR, Brady JL, Mikhaeel NG, Hoppe BS, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig JL, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine LS, Eich HT, Wirth A, Hoppe RT.

Blood. 2020 Mar 25. pii: blood.2019003877. doi: 10.1182/blood.2019003877. [Epub ahead of print]

PMID:
32211877
2.

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.

Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, Beaupre DM, Neuenburg JK, Palomba ML.

Br J Haematol. 2020 Mar 16. doi: 10.1111/bjh.16424. [Epub ahead of print]

PMID:
32180219
3.

Systematic review of whole genome sequencing data to predict phenotypic drug resistance and susceptibility in Swedish Mycobacterium tuberculosis isolates 2016-2018.

Enkirch T, Werngren J, Groenheit R, Alm E, Advani R, Lind Karlberg M, Mansjö M.

Antimicrob Agents Chemother. 2020 Mar 2. pii: AAC.02550-19. doi: 10.1128/AAC.02550-19. [Epub ahead of print]

PMID:
32122893
4.

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.

LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R.

Br J Haematol. 2020 Feb 12. doi: 10.1111/bjh.16499. [Epub ahead of print] No abstract available.

PMID:
32048731
5.

An Assessment of the Knowledge, Attitudes, and Practices of Patients and Families with Diagnoses of Hereditary Neuromuscular Disorders.

Mohiuddin Ahmed H, Advani R, Arif AA, Khan S.

Neuroepidemiology. 2020 Feb 4:1-7. doi: 10.1159/000505330. [Epub ahead of print]

PMID:
32018248
6.

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.

Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ.

Blood Adv. 2020 Jan 28;4(2):253-262. doi: 10.1182/bloodadvances.2019000875.

7.

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.

Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A.

Blood. 2020 Mar 5;135(10):735-742. doi: 10.1182/blood.2019003127.

PMID:
31945149
8.

Mechanical thrombectomy: Lessons to be learned from intravenous thrombolysis.

Advani R, Ajmi S, Kurz MW.

Brain Behav. 2020 Jan;10(1):e01500. doi: 10.1002/brb3.1500. Epub 2019 Dec 13. No abstract available.

9.

Frequency of Early Morbidities in Low Birth Weight Neonates at The Aga Khan University Hospital, Karachi.

Chand S, Ahmed F, Shah MH, Leghari AL, Usman P, Advani R, Salat MS, Ariff S.

Cureus. 2019 Nov 3;11(11):e6061. doi: 10.7759/cureus.6061.

10.

Updates in Treatment Strategies for Hodgkin Lymphoma.

Advani RH.

J Natl Compr Canc Netw. 2019 Nov;17(11.5):1411-1413. doi: 10.6004/jnccn.2019.5027.

PMID:
31766016
11.

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.

Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Montoto S, Chiattone C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M.

Am J Hematol. 2020 Feb;95(2):151-155. doi: 10.1002/ajh.25674. Epub 2019 Nov 25.

PMID:
31709579
12.

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, de Jong D, Sehn LH, Maucort-Boulch D.

J Clin Oncol. 2019 Dec 10;37(35):3359-3368. doi: 10.1200/JCO.19.00743. Epub 2019 Sep 9.

13.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.

Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Acta Haematol. 2020;143(1):40-50. doi: 10.1159/000500666. Epub 2019 Jul 17.

PMID:
31315113
14.

Reducing door-to-needle times in stroke thrombolysis to 13 min through protocol revision and simulation training: a quality improvement project in a Norwegian stroke centre.

Ajmi SC, Advani R, Fjetland L, Kurz KD, Lindner T, Qvindesland SA, Ersdal H, Goyal M, Kvaløy JT, Kurz M.

BMJ Qual Saf. 2019 Nov;28(11):939-948. doi: 10.1136/bmjqs-2018-009117. Epub 2019 Jun 29.

PMID:
31256015
15.

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, Augustson B, Marlton P, Commerford SR, Okrah K, Liu L, Murray E, Penuel E, Ward AF, Flinn IW.

Oncotarget. 2019 Jun 4;10(38):3827-3830. doi: 10.18632/oncotarget.27011. eCollection 2019 Jun 4.

16.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029.

PMID:
31200358
17.

Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.

Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, Crandall JP, de Boer IH, Elliott TG, Galecki AT, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Lingvay I, Maahs DM, McGill JB, Molitch ME, Perkins BA, Pop-Busui R, Pragnell M, Rosas SE, Rossing P, Senior P, Sigal RJ, Spino C, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M, Doria A; PERL Study Group.

Diabetes Care. 2019 Aug;42(8):1454-1463. doi: 10.2337/dc19-0342. Epub 2019 Jun 11.

PMID:
31186299
18.

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J.

Lancet Haematol. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29.

PMID:
30935953
19.

Endovascular Thrombectomy in the Elderly: Do Radiological and Clinical Outcomes Differ from Those in Younger Patients? A Prospective Single-Center Experience.

Rezai MK, Advani R, Dalen I, Fjetland L, Kurz KD, Kurz MW.

Cerebrovasc Dis. 2019;47(1-2):65-71. doi: 10.1159/000497315. Epub 2019 Feb 26.

PMID:
30808821
20.

Reply to J. Wang et al.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2019 Mar 20;37(9):755-757. doi: 10.1200/JCO.18.01907. Epub 2019 Feb 12. No abstract available.

PMID:
30753108

Supplemental Content

Loading ...
Support Center